Nektar Therapeutics (NKTR) Misses Q1 EPS by 69c, Miss on Revenues

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. STZ
5. SKYD
6. HALO
7. BBIO
8. SPY
9. RCKT
10. CRWV

Go back to Nektar Therapeutics (NKTR) Misses Q1 EPS by 69c, Miss on Revenues

Nektar Therapeutics Reports Financial Results for the First Quarter of 2018

May 10, 2018 4:10 PM EDT

SAN FRANCISCO, May 10, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2018.

Cash and investments in marketable securities at March 31, 2018 were $333.8 million as compared to $353.2 million at December 31, 2017. This does not include the $1.0 billion upfront payment and $850.0 million share purchase proceeds received on April 3, 2018, as a result of our new Bristol-Myers Squibb collaboration.

"Nektar begins 2018 in a very strong position with a major collaboration with Bristol-Myers Squibb for NKTR-214 and key advancements in our immuno-oncology and immunology pipeline,"... More